Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

OBJECTIVE: To evaluate the efficacy and safety of subcutaneous peginterferon beta-1a over 2 years in patients with relapsing–remitting multiple sclerosis in the ADVANCE study. METHODS: Patients were randomized to placebo or 125 µg peginterferon beta-1a every 2 or 4 weeks. For Year 2 (Y2), patients o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kieseier, Bernd C, Arnold, Douglas L, Balcer, Laura J, Boyko, Alexey A, Pelletier, Jean, Liu, Shifang, Zhu, Ying, Seddighzadeh, Ali, Hung, Serena, Deykin, Aaron, Sheikh, Sarah I, Calabresi, Peter A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512519/
https://www.ncbi.nlm.nih.gov/pubmed/25432952
http://dx.doi.org/10.1177/1352458514557986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512519/
https://www.ncbi.nlm.nih.gov/pubmed/25432952
http://dx.doi.org/10.1177/1352458514557986

Ejemplares similares